Executive Consultant, Biotech/Pharma
Mark Erwin is an experienced Commercial Operations Executive of start-up and commercial stage biotechnology companies, both private and public, with special therapeutic expertise in oncology/hematology, gastroenterology, neurology and rheumatology and including therapeutics, device and advanced diagnostics.
Mark received his Bachelors of Science from Purdue University in the field of Chemistry, and has combined his passion for science with the art of commercializing biologics. As an active reimbursement & patient advocate, Mark serves as policy committee co-chair for the 21st Century Medicine Coalition, which represents some of the world’s most innovative diagnostic technology companies, clinical laboratories, researchers, physicians, venture capitalists, and patient advocacy groups – all linked by a common mission to develop and make available state-of-the-art diagnostics that improve patient health. Mark was part of the inaugural team that developed, lobbied and gained passage of new federal legislation creating market-based reimbursement possible for several products.
As a commercial operations leader, Mark has been involved in the product launch, planning and execution of many specialty drugs, including Gemzar, Rituxan, Zevalin, Targretin, Excelbine, Proleukin (re-launch), AnserIFX and AnserADA, IBD-sgi, Sucraid, and more. His experience spans across all areas of commercialization; from launch planning & infrastructure to contracting & payer strategy, operations, strategic marketing as well as being a primary commercial spokesperson for investor relations, investor calls and investor industry meetings.